Johanna Buchroithner

Linz, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Glioblastoma radiomics can delineate systemic immune activity states like blood abundance of T cell populations or transcription factors.

Glioblastoma radiomics can delineate systemic immune activity states like blood abundance of T cell populations or transcription factors.

Journal: Journal of neuroinflammation

Published: September 22, 2025

Towards integrating imaging and immunology in glioblastoma: mapping blood immune system metrics to tumor magnetic resonance image data.

Towards integrating imaging and immunology in glioblastoma: mapping blood immune system metrics to tumor magnetic resonance image data.

Journal: Acta neuropathologica communications

Published: August 30, 2024

MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy.

MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy.

Journal: Cancers

Published: January 28, 2022

Combined proteomics/miRNomics of dendritic cell immunotherapy-treated glioblastoma patients as a screening for survival-associated factors.

Combined proteomics/miRNomics of dendritic cell immunotherapy-treated glioblastoma patients as a screening for survival-associated factors.

Journal: NPJ vaccines

Published: July 09, 2019

Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables.

Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables.

Journal: Acta neuropathologica communications

Published: August 26, 2018

Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial.

Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial.

Journal: Cancers

Published: August 24, 2018

The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space.

The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space.

Journal: Nature medicine

Published: June 24, 2017

Vascular endothelia growth factor targeted therapy may improve the effect of dendritic cell-based cancer immune therapy.

Vascular endothelia growth factor targeted therapy may improve the effect of dendritic cell-based cancer immune therapy.

Journal: International journal of clinical pharmacology and therapeutics

Published: December 11, 2013

A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07).

A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07).

Journal: Neuro-oncology

Published: December 07, 2013

Relative survival of patients with non-malignant central nervous system tumours: a descriptive study by the Austrian Brain Tumour Registry.

Relative survival of patients with non-malignant central nervous system tumours: a descriptive study by the Austrian Brain Tumour Registry.

Journal: British journal of cancer

Published: July 24, 2013

AIRP best cases in radiologic-pathologic correlation: human coenurosis (Taenia Larva).

AIRP best cases in radiologic-pathologic correlation: human coenurosis (Taenia Larva).

Journal: Radiographics : a review publication of the Radiological Society of North America, Inc

Published: March 14, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026